The randomizedstudy Functional Assessment of Cancer Therapy–Lung Cancer in non-smallcell lung cancer patients revealed that the humanized anti-IL-6 antibody(ALD518) delayed cachexia by reducing weight loss from 1.5 kg/month to 0.19kg/month and increased the relapse-free survival time patients by 2.2 months[62]. This evidence concerns the gene IL6 and lung carcinoma.